Millendo Therapeutics announced that it has acquired Alizé Pharma SAS in a stock-based transaction. 

“The acquisition of Alizé Pharma SAS transforms Millendo into an innovative endocrinology company with two first-in-class, late-stage clinical assets and a presence in both the United States and Europe. With livoletide, we have acquired a promising asset that has demonstrated encouraging efficacy and tolerability in a Phase 2 clinical trial in PWS,” said Julia C. Owens, Ph.D., president and chief executive officer of Millendo Therapeutics. 

Alizé Pharma’s lead drug candidate, livoletide (previously known as AZP-531) demonstrated positive results in reducing hyperphagia in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in PWS in 2016. PWS is a rare genetic disease characterized by hyperphagia (insatiable hunger), which can lead to obesity-related complications and result in early death. 

The company will operate as Millendo Therapeutics, Inc. in the United States and as Millendo Therapeutics SAS in France and Europe where it will continue to operate the former Alizé Pharma SAS facilities, maintain its capabilities and team and serve as Millendo’s European research and development base.